Serum, plasma and saliva biomarkers for head and neck cancer

References

• Marcu LG, Yeoh E. A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment. J Cancer Res Clin Oncol. 2009;135(10):1303–1314.
   PubMed Web of Science ®Google Scholar
• Arantes LM, De Carvalho AC, Melendez ME, et al. Methylation as a biomarker for head and neck cancer. Oral Oncol. 2014;50(6):587–592.
   PubMed Web of Science ®Google Scholar
• Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9–22.
   PubMed Web of Science ®Google Scholar
• Yao JJ, Lin L, Jin YN, et al. Prognostic value of serum EBV antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment EBV DNA. Cancer science. 2017;108(8):1640–1647.
   Web of Science ®Google Scholar
• Ovchinnikov DA, Cooper MA, Pandit P, et al. Tumor-suppressor gene promoter hypermethylation in saliva of head and neck cancer patients. Transl Oncol. 2012;5(5):321–326.
   PubMed Web of Science ®Google Scholar
• Schafer CA, Schafer JJ, Yakob M, et al. Saliva diagnostics: utilizing oral fluids to determine health status. Monogr Oral Sci. 2014;24:88–98.
   PubMedGoogle Scholar
• Kaczor-Urbanowicz KE, Martin Carreras-Presas C, Kaczor T, et al. Emerging technologies for salivaomics in cancer detection. J Cell Mol Med. 2017;21(4):640–647.
   PubMed Web of Science ®Google Scholar
• Good DM, Thongboonkerd V, Novak J, et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res. 2007;6(12):4549–4555.
   PubMed Web of Science ®Google Scholar
• Wu JY, Yi C, Chung HR, et al. Potential biomarkers in saliva for oral squamous cell carcinoma. Oral Oncol. 2010;46(4):226–231.
   PubMed Web of Science ®Google Scholar
• Rogers E. Blood: physiology and circulation. New York (NY): Britannica Educational Publishing; 2011.
   Google Scholar
• Federick A, Battelhein WHB, Campbell MK, et al. Introduction to general, organic and biochemistry. Boston (MA): Brooks/cole - Cengage learning; 2013.
   Google Scholar
• Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426–437.
   PubMed Web of Science ®Google Scholar
• Kaufman E, Lamster IB. The diagnostic applications of saliva – a review. Crit Rev Oral Biol Med. 2002;13(2):197–212.
   PubMedGoogle Scholar
• Lee YH, Wong DT. Saliva: an emerging biofluid for early detection of diseases. Am J Dent. 2009;22(4):241–248.
   PubMed Web of Science ®Google Scholar
• Liu J, Saliva: DY. A potential media for disease diagnostics and monitoring. Oral Oncol. 2012;48(7):569–577.
   PubMed Web of Science ®Google Scholar
• Amerongen AV, Veerman EC. Saliva – the defender of the oral cavity. Oral Dis. 2002;8(1):12–22.
   PubMed Web of Science ®Google Scholar
• Jankowska AK, Waszkiel D, Kobus A, et al. [Saliva as a main component of oral cavity ecosystem. Part II. Defense mechanisms]. Wiad Lek. 2007;60(5–6):253–257.
   PubMedGoogle Scholar
• Buczko P, Zalewska A, Szarmach I. Saliva and oxidative stress in oral cavity and in some systemic disorders. J Physiol Pharmacol. 2015;66(1):3–9.
   PubMed Web of Science ®Google Scholar
• Mikkonen JJ, Singh SP, Herrala M, et al. Salivary metabolomics in the diagnosis of oral cancer and periodontal diseases. J Periodontal Res. 2016;51(4):431–437.
   PubMed Web of Science ®Google Scholar
• Lim Y, Sun CX, Tran P, et al. Salivary epigenetic biomarkers in head and neck squamous cell carcinomas. Biomark Med. 2016;10(3):301–313.
   PubMed Web of Science ®Google Scholar
• Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genetics. 2009;10(1):57–63.
   PubMed Web of Science ®Google Scholar
• Larrea E, Sole C, Manterola L, et al. New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies. Int J Mol Sci. 2016;17:5.
   Web of Science ®Google Scholar
• Li Y, St John MA, Zhou X, et al. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res. 2004;10(24):8442–8450.
   PubMed Web of Science ®Google Scholar
• Elashoff D, Zhou H, Reiss J, et al. Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev. 2012;21(4):664–672.
   PubMed Web of Science ®Google Scholar
• Michailidou E, Tzimagiorgis G, Chatzopoulou F, et al. Salivary mRNA markers having the potential to detect oral squamous cell carcinoma segregated from oral leukoplakia with dysplasia. Cancer Epidemiol. 2016;43:112–118.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Sharma SC, Das SN. Galectin-1 and galectin-3: plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population. Clin Chim Acta. 2015;442:13–21.
   PubMed Web of Science ®Google Scholar
• Bu J, Bu X, Liu B, et al. Increased expression of tissue/salivary transgelin mRNA predicts poor prognosis in patients with oral squamous cell carcinoma (OSCC). Med Sci Monit. 2015;21:2275–2281.
   PubMed Web of Science ®Google Scholar
• Chai RC, Lim Y, Frazer IH, et al. A pilot study to compare the detection of HPV-16 biomarkers in salivary oral rinses with tumour p16(INK4a) expression in head and neck squamous cell carcinoma patients. BMC Cancer. 2016;16:178.
   PubMed Web of Science ®Google Scholar
• Denaro N, Merlano MC, Russi EG, et al. Non coding RNAs in head and neck squamous cell carcinoma (HNSCC): a clinical perspective. Anticancer Res. 2014;34(12):6887–6896.
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V, et al. Elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;5:843–854.
   Web of Science ®Google Scholar
• Spielmann N, Wong DT. Saliva: diagnostics and therapeutic perspectives. Oral Dis. 2011;17(4):345–354.
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838.
   PubMed Web of Science ®Google Scholar
• Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704–714.
   PubMed Web of Science ®Google Scholar
• Allegra A, Alonci A, Campo S, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41(6):1897–1912.
   PubMed Web of Science ®Google Scholar
• Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56(11):1733–1741.
   PubMed Web of Science ®Google Scholar
• Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16):7223–7233.
   PubMed Web of Science ®Google Scholar
• Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–383.
   PubMed Web of Science ®Google Scholar
• Lo Cicero L, Madesis P, Tsaftaris A, et al. Tobacco plants over-expressing the sweet orange tau glutathione transferases (CsGSTUs) acquire tolerance to the diphenyl ether herbicide fluorodifen and to salt and drought stresses. Phytochemistry. 2015;116:69–77.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Das S. Profiling cell-free and circulating miRNA: a clinical diagnostic tool for different cancers. Tumour Biol. 2016;37(5):5705–5714.
   PubMedGoogle Scholar
• Dreyer F, Biogenesis BA. Functions of exosomes and extracellular vesicles. Methods Mol Biol. 2016;1448:201–216.
   PubMedGoogle Scholar
• Frediani JN, Fabbri M. Essential role of miRNAs in orchestrating the biology of the tumor microenvironment. Mol Cancer. 2016;15(1):42.
   PubMed Web of Science ®Google Scholar
• Blondal T, Jensby Nielsen S, Baker A, et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods. 2013;59(1):S1–6.
   PubMed Web of Science ®Google Scholar
• Wu BH, Xiong XP, Jia J, et al. MicroRNAs: new actors in the oral cancer scene. Oral Oncol. 2011;47(5):314–319.
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513–10518.
   PubMed Web of Science ®Google Scholar
• Abd-El-Fattah AA, Sadik NA, Shaker OG, et al. Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochem Biophys. 2013;67(3):875–884.
   PubMed Web of Science ®Google Scholar
• Park NJ, Zhou H, Elashoff D, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009;15(17):5473–5477.
   PubMed Web of Science ®Google Scholar
• Wiklund ED, Gao S, Hulf T, et al. MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma. PloS One. 2011;6(11):e27840.
   PubMed Web of Science ®Google Scholar
• Momen-Heravi F, Trachtenberg AJ, Kuo WP, et al. Genomewide study of salivary microRNAs for detection of oral cancer. J Dent Res. 2014;93(7 Suppl):86S–93S.
   PubMed Web of Science ®Google Scholar
• Salazar C, Nagadia R, Pandit P, et al. A novel saliva-based microRNA biomarker panel to detect head and neck cancers. Cell Oncol (Dordr). 2014;37(5):331–338.
   PubMed Web of Science ®Google Scholar
• Lin SC, Liu CJ, Lin JA, et al. miR-24 up-regulation in oral carcinoma: positive association from clinical and in vitro analysis. Oral Oncol. 2010;46(3):204–208.
   PubMed Web of Science ®Google Scholar
• Yang CC, Hung PS, Wang PW, et al. miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. J Oral Pathology Medicine. 2011;40(5):397–404.
   PubMed Web of Science ®Google Scholar
• Liu CJ, Tsai MM, Tu HF, et al. miR-196a overexpression and miR-196a2 gene polymorphism are prognostic predictors of oral carcinomas. Ann Surg Oncol. 2013;20(Suppl 3):S406–414.
   PubMed Web of Science ®Google Scholar
• Lu YC, Chen YJ, Wang HM, et al. Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. Cancer Prev Res (Phila) . 2012;5(4):665–674.
   PubMed Web of Science ®Google Scholar
• Liu CJ, Lin JS, Cheng HW, et al. Plasma miR-187* is a potential biomarker for oral carcinoma. Clin Oral Investig. 2017;21(4):1131–1138.
   PubMed Web of Science ®Google Scholar
• Wang JL, Wang X, Yang D, et al. The expression of microRNA-155 in plasma and tissue is matched in human laryngeal squamous cell carcinoma. Yonsei Med J. 2016;57(2):298–305.
   PubMed Web of Science ®Google Scholar
• Wang S, Mo Y, Midorikawa K, et al. The potent tumor suppressor miR-497 inhibits cancer phenotypes in nasopharyngeal carcinoma by targeting ANLN and HSPA4L. Oncotarget. 2015;6(34):35893–35907.
   PubMed Web of Science ®Google Scholar
• Zeng X, Xiang J, Wu M, et al. Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PloS One. 2012;7(10):e46367.
   PubMed Web of Science ®Google Scholar
• Lu YC, Chang JT, Huang YC, et al. Combined determination of circulating miR-196a and miR-196b levels produces high sensitivity and specificity for early detection of oral cancer. Clin Biochem. 2015;48(3):115–121.
   PubMed Web of Science ®Google Scholar
• Wei L, Mao M, Liu H. Droplet digital PCR and qRT-PCR to detect circulating miR-21 in laryngeal squamous cell carcinoma and pre-malignant laryngeal lesions. Acta Otolaryngol. 2016;136(9):923–932.
   PubMed Web of Science ®Google Scholar
• Severino P, Oliveira LS, Andreghetto FM, et al. Small RNAs in metastatic and non-metastatic oral squamous cell carcinoma. BMC Med Genomics. 2015;8:31.
   PubMed Web of Science ®Google Scholar
• Summerer I, Unger K, Braselmann H, et al. Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients. Br J Cancer. 2015;113(1):76–82.
   PubMed Web of Science ®Google Scholar
• Liu X, Luo HN, Tian WD, et al. Diagnostic and prognostic value of plasma microRNA deregulation in nasopharyngeal carcinoma. Cancer Biol Ther. 2013;14(12):1133–1142.
   PubMed Web of Science ®Google Scholar
• Liu N, Cui RX, Sun Y, et al. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. Int J Cancer. 2014;134(6):1359–1368.
   PubMed Web of Science ®Google Scholar
• Sun L, Liu L, Fu H, et al. Association of decreased expression of serum miR-9 with poor prognosis of oral squamous cell carcinoma patients. Med Sci Monit. 2016;22:289–294.
   PubMed Web of Science ®Google Scholar
• Xu H, Yang Y, Zhao H, et al. Serum miR-483-5p: a novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma. Tumour Biol. 2016;37(1):447–453.
   PubMedGoogle Scholar
• Liu CJ, Lin SC, Yang CC, et al. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck. 2012;34(2):219–224.
   PubMed Web of Science ®Google Scholar
• Liu CJ, Kao SY, Tu HF, et al. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 2010;16(4):360–364.
   PubMed Web of Science ®Google Scholar
• Duz MB, Karatas OF, Guzel E, et al. Identification of miR-139-5p as a saliva biomarker for tongue squamous cell carcinoma: a pilot study. Cell Oncol (Dordr) . 2016;39(2):187–193.
   PubMed Web of Science ®Google Scholar
• Wong TS, Liu XB, Wong BY, et al. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res. 2008;14(9):2588–2592.
   PubMed Web of Science ®Google Scholar
• Yilmaz SS, Guzel E, Karatas OF, et al. MiR-221 as a pre- and postoperative plasma biomarker for larynx cancer patients. Laryngoscope. 2015;125(12):E377–381.
   PubMed Web of Science ®Google Scholar
• Hsu CM, Lin PM, Wang YM, et al. Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. Tumour Biol. 2012;33(6):1933–1942.
   PubMedGoogle Scholar
• Zhang G, Zong J, Lin S, et al. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment. Int J Cancer. 2015;136(5):E301–312.
   PubMed Web of Science ®Google Scholar
• Lu J, Xu X, Liu X, et al. Predictive value of miR-9 as a potential biomarker for nasopharyngeal carcinoma metastasis. Br J Cancer. 2014;110(2):392–398.
   PubMed Web of Science ®Google Scholar
• Hou B, Ishinaga H, Midorikawa K, et al. Circulating microRNAs as novel prognosis biomarkers for head and neck squamous cell carcinoma. Cancer Biol Ther. 2015;16(7):1042–1046.
   PubMed Web of Science ®Google Scholar
• Summerer I, Niyazi M, Unger K, et al. Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients. Radiat Oncol. 2013;8:296.
   PubMed Web of Science ®Google Scholar
• Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9(6):703–719.
   PubMed Web of Science ®Google Scholar
• Qiu MT, Hu JW, Yin R, et al. Long noncoding RNA: an emerging paradigm of cancer research. Tumour Biol. 2013;34(2):613–620.
   PubMedGoogle Scholar
• Brown CJ, Ballabio A, Rupert JL, et al. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature. 1991;349(6304):38–44.
   PubMed Web of Science ®Google Scholar
• Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007;129(7):1311–1323.
   PubMed Web of Science ®Google Scholar
• Kino T, Hurt DE, Ichijo T, et al. Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci Signal. 2010;3(107):ra8.
   PubMed Web of Science ®Google Scholar
• Wang X, Arai S, Song X, et al. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature. 2008;454(7200):126–130.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhou Y, Lu J, et al. Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. Med Oncol. 2014;31(9):148.
   PubMed Web of Science ®Google Scholar
• Tang H, Wu Z, Zhang J, et al. Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. Mol Med Rep. 2013;7(3):761–766.
   PubMed Web of Science ®Google Scholar
• Fayda M, Isin M, Tambas M, et al. Do circulating long non-coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) predict the treatment response in patients with head and neck cancer treated with chemoradiotherapy? Tumour Biol. 2016;37(3):3969–3978.
   PubMedGoogle Scholar
• The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–582.
   PubMed Web of Science ®Google Scholar
• Wang Y, Springer S, Mulvey CL, et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015;7(293):293ra104.
   PubMed Web of Science ®Google Scholar
• Schmidt H, Kulasinghe A, Perry C, et al. A liquid biopsy for head and neck cancers. Expert Rev Mol Diagn. 2016;16(2):165–172.
   PubMed Web of Science ®Google Scholar
• van Ginkel JH, Huibers MMH, Noorlag R, et al. Liquid biopsy: a future tool for posttreatment surveillance in head and neck cancer? Pathobiology. 2017;84(3):115–120.
   PubMed Web of Science ®Google Scholar
• Qiu M, Wang J, Xu Y, et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2015;24(1):206–212.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra224.
   Web of Science ®Google Scholar
• Ahn SM, Chan JY, Zhang Z, et al. Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2014;140(9):846–854.
   PubMed Web of Science ®Google Scholar
• Puttipanyalears C, Subbalekha K, Mutirangura A, et al. Alu hypomethylation in smoke-exposed epithelia and oral squamous carcinoma. Asian Pac J Cancer Prev. 2013;14(9):5495–5501.
   PubMedGoogle Scholar
• Righini CA, De Fraipont F, Timsit JF, et al. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res. 2007;13(4):1179–1185.
   PubMed Web of Science ®Google Scholar
• Rosas SL, Koch W, da Costa Carvalho MG, et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 2001;61(3):939–942.
   PubMed Web of Science ®Google Scholar
• Nagata S, Hamada T, Yamada N, et al. Aberrant DNA methylation of tumor-related genes in oral rinse: a noninvasive method for detection of oral squamous cell carcinoma. Cancer. 2012;118(17):4298–4308.
   PubMed Web of Science ®Google Scholar
• Schussel J, Zhou XC, Zhang Z, et al. EDNRB and DCC salivary rinse hypermethylation has a similar performance as expert clinical examination in discrimination of oral cancer/dysplasia versus benign lesions. Clin Cancer Res. 2013;19(12):3268–3275.
   PubMed Web of Science ®Google Scholar
• Pattani KM, Zhang Z, Demokan S, et al. Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) . 2010;3(9):1093–1103.
   PubMed Web of Science ®Google Scholar
• Demokan S, Chang X, Chuang A, et al. KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses. Int J Cancer. 2010;127(10):2351–2359.
   PubMed Web of Science ®Google Scholar
• Guerrero-Preston R, Soudry E, Acero J, et al. NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva. Cancer Prev Res (Phila) . 2011;4(7):1061–1072.
   PubMed Web of Science ®Google Scholar
• Ferlazzo N, Curro M, Zinellu A, et al. Influence of MTHFR genetic background on p16 and MGMT methylation in oral squamous cell cancer. Int J Mol Sci. 2017;18:4.
   Web of Science ®Google Scholar
• Langevin SM, Stone RA, Bunker CH, et al. MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis. 2010;31(5):864–870.
   PubMed Web of Science ®Google Scholar
• Carvalho AL, Jeronimo C, Kim MM, et al. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res. 2008;14(1):97–107.
   PubMed Web of Science ®Google Scholar
• Gaykalova DA, Vatapalli R, Wei Y, et al. Outlier analysis defines zinc finger gene family DNA methylation in tumors and saliva of head and neck cancer patients. PloS One. 2015;10(11):e0142148.
   PubMed Web of Science ®Google Scholar
• Lim Y, Wan Y, Vagenas D, et al. Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers. BMC Cancer. 2016;16(1):749.
   PubMed Web of Science ®Google Scholar
• Viet CT, Schmidt BL. Methylation array analysis of preoperative and postoperative saliva DNA in oral cancer patients. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3603–3611.
   PubMed Web of Science ®Google Scholar
• Chang HW, Chan A, Kwong DL, et al. Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient. Int J Cancer. 2003;105(6):851–855.
   PubMed Web of Science ®Google Scholar
• Chang HW, Chan A, Kwong DL, et al. Detection of hypermethylated RIZ1 gene in primary tumor, mouth, and throat rinsing fluid, nasopharyngeal swab, and peripheral blood of nasopharyngeal carcinoma patient. Clin Cancer Res. 2003;9(3):1033–1038.
   PubMed Web of Science ®Google Scholar
• Mydlarz WK, Hennessey PT, Wang H, et al. Serum biomarkers for detection of head and neck squamous cell carcinoma. Head Neck. 2016;38(1):9–14.
   PubMed Web of Science ®Google Scholar
• Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 2000;60(4):892–895.
   PubMed Web of Science ®Google Scholar
• Wong TS, Man MW, Lam AK, et al. The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. Eur J Cancer. 2003;39(13):1881–1887.
   PubMed Web of Science ®Google Scholar
• Wong TS, Chang HW, Tang KC, et al. High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients. Clin Cancer Res. 2002;8(2):433–437.
   PubMed Web of Science ®Google Scholar
• Carvalho AL, Henrique R, Jeronimo C, et al. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance. Clin Cancer Res. 2011;17(14):4782–4789.
   PubMed Web of Science ®Google Scholar
• Schrock A, Leisse A, de Vos L, et al. Free-circulating methylated DNA in blood for diagnosis, staging, prognosis, and monitoring of head and neck squamous cell carcinoma patients: an observational prospective cohort study. Clin Chem. 2017;63(7):1288–1296.
   PubMed Web of Science ®Google Scholar
• Rettori MM, De Carvalho AC, Bomfim Longo AL, et al. Prognostic significance of TIMP3 hypermethylation in post-treatment salivary rinse from head and neck squamous cell carcinoma patients. Carcinogenesis. 2013;34(1):20–27.
   PubMed Web of Science ®Google Scholar
• Sun W, Zaboli D, Wang H, et al. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer. Clin Cancer Res. 2012;18(4):1082–1091.
   PubMed Web of Science ®Google Scholar
• Nakahara Y, Shintani S, Mihara M, et al. Detection of p16 promoter methylation in the serum of oral cancer patients. Int J Oral Maxillofac Surg. 2006;35(4):362–365.
   PubMed Web of Science ®Google Scholar
• Li HP, Peng CC, Chung IC, et al. Aberrantly hypermethylated Homeobox A2 derepresses metalloproteinase-9 through TBP and promotes invasion in Nasopharyngeal carcinoma. Oncotarget. 2013;4(11):2154–2165.
   PubMed Web of Science ®Google Scholar
• Wong TS, Kwong DL, Sham JS, et al. Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin Cancer Res. 2004;10(7):2401–2406.
   PubMed Web of Science ®Google Scholar
• Ma HL, Yu C, Liu Y, et al. Decreased expression of glutathione S-transferase pi correlates with poorly differentiated grade in patients with oral squamous cell carcinoma. J Oral Pathology Medicine. 2015;44(3):193–200.
   PubMed Web of Science ®Google Scholar
• Holzinger D, Wichmann G, Baboci L, et al. Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma. Int J Cancer. 2017;140(12):2748–2757.
   PubMed Web of Science ®Google Scholar
• Kakurina GV, Kondakova IV, Cheremisina OV, et al. Adenylyl cyclase-associated protein 1 in the development of head and neck squamous cell carcinomas. Bull Exp Biol Med. 2016;160(5):695–697.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Johansson M, Waterboer T, et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol. 2013;31(21):2708–2715.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Shimada H, Tanaka S, et al. Serum midkine as a biomarker for malignancy, prognosis, and chemosensitivity in head and neck squamous cell carcinoma. Cancer Med. 2016;5(3):415–425.
   PubMed Web of Science ®Google Scholar
• Chai YD, Zhang L, Yang Y, et al. Discovery of potential serum protein biomarkers for lymph node metastasis in oral cancer. Head Neck. 2016;38(1):118–125.
   PubMed Web of Science ®Google Scholar
• Tian WD, Li JZ, Hu SW, et al. Proteomic identification of alpha-2-HS-glycoprotein as a plasma biomarker of hypopharyngeal squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8(8):9021–9031.
   PubMed Web of Science ®Google Scholar
• Warawdekar UM, Zingde SM, Iyer KS, et al. Elevated levels and fragmented nature of cellular fibronectin in the plasma of gastrointestinal and head and neck cancer patients. Clin Chim Acta. 2006;372(1–2):83–93.
   PubMed Web of Science ®Google Scholar
• Li Y, Li L, Wang JT, et al. Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis. Med Oncol. 2012;29(3):1429–1434.
   PubMed Web of Science ®Google Scholar
• Petrik D, Lavori PW, Cao H, et al. Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol. 2006;24(33):5291–5297.
   PubMed Web of Science ®Google Scholar
• Lim AM, Rischin D, Fisher R, et al. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clin Cancer Res. 2012;18(1):301–307.
   PubMed Web of Science ®Google Scholar
• Hsin CH, Chen MK, Tang CH, et al. High level of plasma matrix metalloproteinase-11 is associated with clinicopathological characteristics in patients with oral squamous cell carcinoma. PloS One. 2014;9(11):e113129.
   PubMed Web of Science ®Google Scholar
• Patel BP, Shah SV, Shukla SN, et al. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck. 2007;29(6):564–572.
   PubMed Web of Science ®Google Scholar
• Pradhan-Palikhe P, Vesterinen T, Tarkkanen J, et al. Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer. Oral Oncol. 2010;46(7):514–518.
   PubMed Web of Science ®Google Scholar
• Su CW, Huang YW, Chen MK, et al. Polymorphisms and plasma levels of tissue inhibitor of metalloproteinase-3: impact on genetic susceptibility and clinical outcome of oral cancer. Medicine (Baltimore) . 2015;94(46):e2092.
   PubMed Web of Science ®Google Scholar
• Peng P, Shen J, Dong JB, et al. Preoperative plasma fibrinogen predicts cervical metastasis in patients with stage I/II carcinoma of the tongue. Int J Oral Maxillofac Surg. 2014;43(4):393–398.
   PubMed Web of Science ®Google Scholar
• Selzer E, Grah A, Heiduschka G, et al. Pre-therapeutic fibrinogen levels are of prognostic significance in locally advanced head and neck cancer. Wien Klin Wochenschr. 2016;128(9–10):320–328.
   PubMed Web of Science ®Google Scholar
• Camisasca DR, Da Ros Goncalves L, Soares MR, et al. A proteomic approach to compare saliva from individuals with and without oral leukoplakia. J Proteomics. 2017;151:43–52.
   PubMed Web of Science ®Google Scholar
• Krapfenbauer K, Drucker E, Thurnher D. Identification of tumour-related proteins as potential screening markers by proteome analysis-protein profiles of human saliva as a predictive and prognostic tool. Epma J. 2014;5(1):20.
   PubMedGoogle Scholar
• Jarai T, Maasz G, Burian A, et al. Mass spectrometry-based salivary proteomics for the discovery of head and neck squamous cell carcinoma. Pathol Oncol Res. 2012;18(3):623–628.
   PubMed Web of Science ®Google Scholar
• Wu CC, Chu HW, Hsu CW, et al. Saliva proteome profiling reveals potential salivary biomarkers for detection of oral cavity squamous cell carcinoma. Proteomics. 2015;15(19):3394–3404.
   PubMed Web of Science ®Google Scholar
• Vidotto A, Henrique T, Raposo LS, et al. Salivary and serum proteomics in head and neck carcinomas: before and after surgery and radiotherapy. Cancer Biomark. 2010;8(2):95–107.
   PubMed Web of Science ®Google Scholar
• Chen YT, Chen HW, Wu CF, et al. Development of a multiplexed liquid chromatography multiple-reaction-monitoring mass spectrometry (LC-MRM/MS) method for evaluation of salivary proteins as oral cancer biomarkers. Mol Cell Proteomics. 2017;16(5):799–811.
   PubMed Web of Science ®Google Scholar
• Yu JS, Chen YT, Chiang WF, et al. Saliva protein biomarkers to detect oral squamous cell carcinoma in a high-risk population in Taiwan. Proc Natl Acad Sci USA. 2016;113(41):11549–11554.
   PubMed Web of Science ®Google Scholar
• Kawahara R, Bollinger JG, Rivera C, et al. A targeted proteomic strategy for the measurement of oral cancer candidate biomarkers in human saliva. Proteomics. 2016;16(1):159–173.
   PubMed Web of Science ®Google Scholar
• Li SX, Yang YQ, Jin LJ, et al. Detection of survivin, carcinoembryonic antigen and ErbB2 level in oral squamous cell carcinoma patients. Cancer Biomark. 2016;17(4):377–382.
   PubMed Web of Science ®Google Scholar
• Allegra E, Trapasso S, La Boria A, et al. Prognostic role of salivary CD44sol levels in the follow-up of laryngeal carcinomas. J Oral Pathology Medicine. 2014;43(4):276–281.
   PubMed Web of Science ®Google Scholar
• Pereira LH, Reis IM, Reategui EP, et al. Risk stratification system for oral cancer screening. Cancer Prev Res (Phila). 2016;9(6):445–455.
   PubMed Web of Science ®Google Scholar